



**MENARINI**  
*group*



## COMPANY PROFILE

8<sup>th</sup> April 2025

Menarini  
was **founded in 1886.**

In 1915 its headquarters  
were established  
in **Florence.**



# Milestones

1886

## Menarini foundation

1964

## International presence

The internationalization of Menarini begins with the opening of **Laboratorios Menarini in Spain**, followed on by **Greece, Portugal, Central America** and **France**.

1978

## Research & Development

Menarini's Research & Development department opened and patents on pharmaceuticals were introduced.

1992

## Central and Eastern Europe

Menarini acquires ex-GDR company **Berlin-Chemie** thanks to which it makes its entry into **Germany** and Central and Eastern Europe.

Since 1992, the Menarini Group has reinvested all profits in its growth

2003

## Menarini Biotech

Opening of Menarini Biotech, specialised in the research, development and manufacturing of biotech pharmaceuticals, from the lab to the patient.

# Milestones

2011

## Asia Pacific

Menarini makes its entry into Asia Pacific thanks to the acquisition of a company based in **Singapore** and present in **13 countries** throughout the region, from China to Australia.

2013-2016

## Silicon Biosystems

Acquisition of Silicon Biosystems, a start-up of innovative technologies for liquid biopsies.

## Cellsearch

Acquisition of Cell Search, an FDA approved technology in the field of **circulating tumor cells**.

2020

## U.S.A.

Menarini makes its entrance into the USA through to the acquisition of **Stemline Therapeutics**, biopharmaceutical company publicly listed on NASDAQ, and their product **Tagraxofusp**, the only FDA approved therapy available for BPDCN, thus strengthening Menarini's presence in oncology.


2023

## FDA & EMA



U.S. FDA and EU (EMA) approve **Elacestrant** as the first treatment for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer.

# Consolidated turnover

Million euro



# Consolidated turnover




# Menarini in the **world**


Present in **140 countries** worldwide (with its affiliates, distributors and franchises)



# Number of employees



# Employees % of graduates and technicians



# 18 manufacturing plants

## EUROPE is the Group's heart of production

In 2024 **609 million packs** were produced at these sites:\*

**Italy** Pisa (2 plants), Florence (2 plants)  
Pomezia\*\*, L'Aquila, Lomagna (Lecco),  
Casaletto Lodigiano (Lodi)

**Spain** Barcelona

**Germany** Berlin (2 plants), Dresden



Plants dedicated to the production for local markets are located in Central America (Guatemala City), Ireland (Shannon), Turkey (Istanbul), Russia (Kaluga) and Indonesia (Jakarta).

U.S.A. (Philadelphia - Huntingdon Valley): diagnostic production



# 9 Research & Development centers



\* Pomezia



# Research & Development Projects

## ONCOLOGY

SOLID TUMORS	COMPOUND	DRUG CLASS (TARGET)	INDICATION	DEVELOPMENT STAGE
	<b>Elacestrant<sup>o</sup></b>	SME (SERD - ER)	Monotherapy: ER+/HER2- Metastatic Breast Cancer ( <i>EMERALD</i> trial)	<b>EMA and FDA: approved</b>
	<b>Elacestrant</b>	SME (SERD - ER)	Monotherapy: CDK4/6 Inhibitor-naïve ER+/HER2- Metastatic Breast Cancer ( <i>ELCIN</i> trial)	<b>Phase II</b>
	<b>Elacestrant</b>	SME (SERD - ER)	Combination therapy: ER+/HER2- Metastatic Breast Cancer ( <i>ELEVATE</i> trial)	<b>Phase II</b>
	<b>Elacestrant</b>	SME (SERD - ER)	Combination therapy: ER+/HER2- Breast Cancer with brain metastasis ( <i>ELECTRA</i> trial)	<b>Phase II</b>
	<b>Elacestrant</b>	SME (SERD - ER)	Combination therapy: ER+/HER2- Metastatic or locally Advanced Breast Cancer ( <i>SUMIT-ELA</i> trial)*	<b>Phase II</b>
	<b>Elacestrant</b>	SME (SERD - ER)	Combination therapy: ER+/HER2- , ESR-1 mut, Advanced Breast Cancer ( <i>ADELA</i> trial)**	<b>Phase III</b>
	<b>Elacestrant</b>	SME (SERD - ER)	Monotherapy: ER+/HER2- early Breast Cancer with a high risk of recurrence ( <i>ELEGANT</i> trial)	<b>Phase III</b>
	<b>SL-701</b>	IT (IL-13Rα2, EphA2, Survivin)	Recurrent Glioblastoma	<b>Phase II</b>
	<b>MEN1309</b>	ADC (Anti-CD205)	Solid Tumors	<b>Phase Ib</b>
<b>Felezonexor</b>	SME (XP01i)	Solid Tumors	<b>Phase Ib</b>	
<b>MEN2312</b>	SME (KAT6i)	Breast Cancer/Solid tumors and HEME malignancies	<b>Phase I</b>	
<b>Selinexor</b>	SME (XP01i)	Endometrial Cancer***	<b>Phase III</b>	
<b>MEN2501</b>	SME	Solid Tumors	<b>Phase I</b>	

HEMATOLOGY	COMPOUND	DRUG CLASS (TARGET)	INDICATION	DEVELOPMENT STAGE
	<b>Tagraxofusp</b>	TB (CD123)	Monotherapy: Blastic plasmacytoid dendritic cell neoplasm (BPDCN)	<b>EMA and FDA: approved</b>
	<b>Tagraxofusp</b>	TB (CD123)	Monotherapy: Chronic myelomonocytic leukemia (CMML)	<b>Phase II</b>
	<b>Tagraxofusp</b>	TB (CD123)	Monotherapy: Myelofibrosis (MF)	<b>Phase II</b>
	<b>Tagraxofusp</b>	TB (CD123)	Combination therapy: Acute Myeloid Leukemia (AML)	<b>Phase II</b>
	<b>MEN1703</b>	SME (PIM/FLT3i)	Combination therapy: Relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL)	<b>Phase II</b>
	<b>Selinexor<sup>oo</sup></b>	SME (XP01i)	Combination therapy: Relapsed/refractory Multiple Myeloma	<b>EMA and FDA: approved</b>
	<b>Selinexor</b>	SME (XP01i)	Combination therapy: Myelofibrosis***	<b>Phase III</b>



<sup>o</sup> <https://www.menarini.com/en-us/news/news-detail/european-commission-approves-menarini-groups-orserdu174-elacestrant-for-the-treatment-of-patients-with-er-her2-locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation>

\* In collaboration with Carrick Therapeutics

\*\* In co-sponsorship with MedSir

\*\*\* Karyopharm trial. Based on the Licensing agreement in force, Menarini has Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries

\*\* <https://www.menarini.com/it-it/news/dettaglio-news/karyopharm-and-menarini-group-receive-full-marketing-authorisation-from-the-european-commission-for-nexpovio174-selinexor-for-the-treatment-of-patients-with-multiple-myeloma-after-at-least-one-prior->

SERD, Selective Estrogen Receptor Degradar; IT, Immunotherapy; SME, Small Molecule Entity; ADC, Antibody Drug Conjugate; TB, Targeted Biologic; SME, Small Molecule Entity

# Research & Development Projects

## ANTI-INFECTIVES

COMPOUND	DRUG CLASS	INDICATION	DEVELOPMENT STAGE
<b>Meropenem + Vaborbactam</b>	Carbapenem + β-lactamase inhibitor	Complicated urinary tract infections, Complicated Intra abdominal infections, Hospital acquired pneumonia, Ventilator associated pneumonia and Bacteremia	<b>EMA, FDA, Hong Kong, Thailand and Macao: approved</b>
<b>Delafloxacin</b>	Anionic fluoroquinolone	Acute Bacterial Skin and Skin Structure - ABSSSI Community Acquired Bacterial Pneumonia - CABP	<b>EMA, FDA, Hong Kong and TITCK (Turkey): approved</b>
<b>Oritavancina</b>	Semisynthetic glycopeptide	Acute Bacterial Skin and Skin Structure - ABSSSI	<b>EMA and FDA: approved</b>
<b>Oritavancina</b> (new formulation)	Semisynthetic glycopeptide	Acute Bacterial Skin and Skin Structure - ABSSSI	<b>EMA and FDA: approved</b>
<b>Cefepime + Taniborbactam</b>	Beta-lactam + β-lactamase inhibitor	Complicated urinary tract and intra abdominal infections, Hospital-acquired bacterial pneumonia and Ventilator-associated bacterial pneumonia	<b>Phase III</b>

# Research & Development Projects

## CARDIO-METABOLIC

COMPOUND	DRUG CLASS	INDICATION	DEVELOPMENT STAGE
<b>Obicetrapib</b>	Cholesteryl ester transfer protein (CETP) inhibitor	Lipid Lowering agent administered to patients previously treated with Maximum Tolerated Lipid-Modifying Therapies not at target for LDL-C  Prevention of Major Adverse CardioVascular events	<b>Phase III</b>
<b>Obicetrapib+Ezetimibe</b>	Cholesteryl ester transfer protein (CETP) inhibitor +  Niemann-Pick C1-like 1 (NPC1L1) protein inhibitor	Lipid Lowering agent administered to patients treated with Maximum Tolerated Lipid-Modifying Therapies not at target for LDL-C	<b>Phase III</b>

# Menarini For People: our social responsibility projects



## Wheelchair basketball

Volpi Rosse Menarini Menarini Joventut. *When sport can help break down barriers and foster inclusion and independence.*



## A pediatrician's network

Help up 15,000 "sentinel doctors" recognise child abuse.



## Together with Red Cross

Contributions to support populations in emergency.



## Menarini Forest

17,000 trees planted in several countries all over the world.



## Standing by children in difficulty

Healthcare, nutrition and education for children from economically disadvantaged families.



## Donations of medicines

To support those in need and promote better health for all.

# Menarini Foundation

The **Fondazione Menarini** was founded in the spring of 1976 to promote research and knowledge in the fields of biology, pharmacology and medicine, but also in the fields of economy and human sciences.



FONDAZIONE  
MENARINI

## Events

More than 600 International Events, 2.000 Speakers and 75.000 attendees.  
Live streaming in 3 languages.



“Think Tank” which, since 2022, promotes initiatives for change on social, economic and cultural issues in Italy.

## House of sciences

More than 3.000 articles available free of charge and video interviews with 10 Nobel laureates.

- **Scientific Library** - 8 therapeutic areas
- **Dialogs Beyond Borders** - video interviews

## Minuti



- **Minuti Science** - Website dedicated to Minuti Science edition.
- **Minuti Art** - Website dedicated to Minuti Art edition.



# Fair Play Menarini Award

**Ethics, loyalty, and respect**



Now in its 29<sup>th</sup> edition, the **Fair Play Menarini International Award** promotes the fundamental values of sport.

The award winners become **Fair Play Ambassadors**, symbolising outstanding sporting feats achieved in the name of fair play and respect.

**Over 400 award winners**, including: Stefan Edberg, Casey Stoner, Ian Thorpe, Edwin Moses, Tommie Smith, Luis Scola, Zico.





**MENARINI**  
*group*

